Collectively, this study provides strong evidence that MALAT1 is indispensable for maintaining genome integrity in advanced-stage prostate cancer, emphasizing a novel therapeutic approach wherein targeting MALAT1 augments sensitivity to PARP inhibition by inducing HR deficiency in prostate cancer. Here, PARP1 is linked to prostate cancer.